Interested in Castle Biosciences, Inc.? Here are five stocks we like better.
Castle Biosciences reported strong Q2 growth, with revenue rising 20% year over year to $103.5 million. The company raised its 2026 revenue outlook to $365 million–$375 million, up from $345 million–$355 million previously.
TissueCypher was the primary growth driver, generating 14,988 reports, up 63% year over year. Castle now expects TissueCypher report volume to increase approximately 50%–52% in 2026, while AdvanceAD-Tx exceeded 1,000 orders in the quarter.
Despite higher revenue, gross margins declined and Castle posted a $2.1 million net loss, although adjusted EBITDA rose to $12.4 million. Management expects positive adjusted EBITDA in Q3, Q4 and for full-year 2026, supported by $266.8 million in cash and investments at quarter-end.
Castle Biosciences (NASDAQ:CSTL) reported second-quarter 2026 revenue of $103.5 million, up 20% from the prior-year period, as growth in its TissueCypher test and other core offerings supported results. The company raised its full-year revenue outlook to $365 million to $375 million, from a previous range of $345 million to $355 million.
#year #quarter
Castle Biosciences reported strong Q2 growth, with revenue rising 20% year over year to $103.5 million. The company raised its 2026 revenue outlook to $365 million–$375 million, up from $345 million–$355 million previously.
TissueCypher was the primary growth driver, generating 14,988 reports, up 63% year over year. Castle now expects TissueCypher report volume to increase approximately 50%–52% in 2026, while AdvanceAD-Tx exceeded 1,000 orders in the quarter.
Despite higher revenue, gross margins declined and Castle posted a $2.1 million net loss, although adjusted EBITDA rose to $12.4 million. Management expects positive adjusted EBITDA in Q3, Q4 and for full-year 2026, supported by $266.8 million in cash and investments at quarter-end.
Castle Biosciences (NASDAQ:CSTL) reported second-quarter 2026 revenue of $103.5 million, up 20% from the prior-year period, as growth in its TissueCypher test and other core offerings supported results. The company raised its full-year revenue outlook to $365 million to $375 million, from a previous range of $345 million to $355 million.
#year #quarter
2 months ago
